The ACER1 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the alkaline ceramidase 1 (ACER1) gene in the PaTu 8988t human pancreatic cancer cell line. This polyclonal format provides a heterogeneous mixture of loss-of-function alleles, enabling robust functional studies without the potential phenotypic bias of a single clone. These cells are designed to dissect the role of ACER1 in sphingolipid metabolism and its impact on cancer cell apoptosis, chemoresistance, and migration.
The parental PaTu 8988t cell line is an epithelial isolate from a liver metastasis of a pancreatic ductal adenocarcinoma, preserving the aggressive features of metastatic disease. This cell line is extensively used to study pancreatic cancer biology, including metastatic progression and intrinsic drug resistance. The ACER1 knockout in this context allows researchers to investigate sphingolipid signaling alterations specifically within a highly malignant, chemoresistant tumor microenvironment.
ACER1 encodes a ceramidase that hydrolyzes ceramides to sphingosine and free fatty acid, occupying a pivotal position in sphingolipid metabolism. This reaction controls the balance between pro-apoptotic ceramides and sphingosine, which is subsequently phosphorylated by sphingosine kinases (SPHK1) to produce sphingosine-1-phosphate (S1P). S1P acts through S1P receptors (e.g., S1PR1) to promote cell survival, proliferation, and migration. ACER1 activity is regulated by upstream signals including p53, cytokines, and cellular stress, and it functionally interacts with ceramide synthases and SPHK1. Disruption of ACER1 leads to ceramide accumulation and reduced S1P, shifting cells toward apoptosis and potentially sensitizing them to chemotherapy.
In pancreatic cancer, dysregulated sphingolipid metabolism contributes to chemoresistance and tumor progression. ACER1 knockout in PaTu 8988t cells offers a model to explore how ceramide/S1P imbalance influences drug sensitivity, particularly to agents like gemcitabine, and may reveal strategies to overcome therapeutic resistance. The polyclonal population also allows for the assessment of heterogeneity in sphingolipid-dependent phenotypes such as apoptosis induction and cell migration, which are critical for metastasis.
Representative research applications include quantitative sphingolipid profiling by LC-MS, apoptosis assays with Annexin V staining, and western blot analysis of pathway components like cleaved caspases, SPHK1, and S1PR1. Cell viability and migration assays further elucidate functional consequences of ACER1 disruption. This product serves as a crucial tool for probing sphingolipid signaling in pancreatic adenocarcinoma and for screening therapeutic interventions targeting ceramide metabolism. For additional technical information, contact Ascent Research.
